Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect

Climb Bio NASDAQ: CLYM outlined its clinical development strategy and upcoming data readouts during a fireside chat at H.C. Wainwright's BioConnect Conference, with management emphasizing two biologic drug programs aimed at immune-mediated diseases, including nephrology and hematology indications.